Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter

Discovery & Development

Discovery & Development COVID-19

Corporate Medicine, Government X-Rays

| Angus Stewart

Pfizer’s trial of a new medicine for COVID-19, produced with support from the US Department of Energy, could improve access to treatment.

Discovery & Development Formulation

The Digital Future of Formulation

| Ferdinand-Paul Brandl

Integrating digital technologies into your operations can make all the difference to the formulation process.

Discovery & Development Technology and Equipment

Reduce, Refine... Replace?

| Tomasz Kostrzewski

Adoption of organ-on-a-chip technology is on the rise, but misconceptions remain prevalent, says Tomasz Kostrzewski of CN Bio.

Discovery & Development Drug Discovery

Checkmate for Cachexia?

| Angus Stewart

An interview with Ken Gruber of Endevica Bio on his work producing a treatment for cachexia, a wasting condition common in late-stage cancer.

Discovery & Development Dosage Forms

Gilead Goes Ferreting

| Angus Stewart

A partnership between Gilead Sciences and Georgia State University has tested a new oral antiviral for COVID-19.

Discovery & Development Business Practice

A Roadmap to Improved Drug Access in the Global South

| Greg S Garrett, Jean-Michel Piedagnel

Two members of the Drugs for Neglected Diseases initiative lay out how they improved access to Hep C treatment in Southeast Asia and beyond.

Discovery & Development COVID-19

Pharma Versus Omicron

| Stephanie Sutton

How will vaccine and therapeutic makers respond to the new SARS-CoV-2 variant?

Discovery & Development Drug Discovery

The Next Frontier in HIV Prevention

| Maryam Mahdi

Exploring the potential of vaccines for treatment equity.

Discovery & Development Drug Discovery

Slowing the Alzheimer’s Decline | The Medicine Maker Social

| Maryam Mahdi

How can the NLRP3 inflammasome can be exploited to slow the decline associated with Alzheimer's disease?

Discovery & Development Drug Discovery

The Tale of Two TULIPs

| Angus Stewart

A drug development journey with origins in the 1950s has finally reached its successful conclusion: a new treatment for lupus.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register